Empiric Antipseudomonal Therapy for Adults
For empiric antipseudomonal coverage in adults, use a single antipseudomonal beta-lactam agent (piperacillin-tazobactam 4.5g IV q6h, cefepime 2g IV q8h, or meropenem 1g IV q8h) in most cases, but escalate to dual antipseudomonal therapy from two different drug classes if the patient has received IV antibiotics within 90 days, is in septic shock, or has high mortality risk. 1
Risk Stratification Determines Therapy Intensity
The 2016 IDSA/ATS guidelines provide clear algorithmic guidance based on patient risk factors:
Low-Risk Patients (No Recent Antibiotics, Not Critically Ill)
- Single antipseudomonal agent is sufficient 1
- Options include:
- Piperacillin-tazobactam 4.5g IV q6h
- Cefepime 2g IV q8h
- Meropenem 1g IV q8h
- Imipenem 500mg IV q6h
- Levofloxacin 750mg IV daily
High-Risk Patients Requiring Dual Coverage
Use two agents from different classes when:
- IV antibiotic use within prior 90 days
- Septic shock present
- Need for ventilatory support
- Structural lung disease (bronchiectasis, cystic fibrosis) 1
Dual therapy combinations (avoid using two beta-lactams together):
- Beta-lactam (above options) PLUS one of:
- Fluoroquinolone (levofloxacin 750mg IV daily OR ciprofloxacin 400mg IV q8h)
- Aminoglycoside (amikacin 15-20mg/kg IV daily, gentamicin 5-7mg/kg IV daily, or tobramycin 5-7mg/kg IV daily)
- Aztreonam 2g IV q8h
Critical Dosing Considerations
Never use aminoglycosides as monotherapy for Pseudomonas—this is strongly contraindicated 1. Aminoglycosides should only be used as part of combination therapy.
Extended or prolonged infusions of beta-lactams significantly improve target attainment. Research demonstrates that standard intermittent infusions often fail to achieve adequate pharmacodynamic targets, while prolonged infusions of cefepime 2g q8h and meropenem 1g q8h achieve >90% probability of target attainment 2. Guideline-concordant dosing reduces treatment failure rates from 62% to 48% 3.
When to De-escalate
Once susceptibility results are available:
- Switch to monotherapy if patient is not in septic shock and mortality risk is low 1
- Continue dual therapy only if patient remains in septic shock or at high mortality risk (>25%) when sensitivities return 1
- Base definitive therapy on susceptibility testing results 1
Special Populations and Contexts
For community-acquired pneumonia with Pseudomonas risk factors (structural lung disease, recent hospitalization, prior Pseudomonas isolation): Use an antipseudomonal beta-lactam plus either an aminoglycoside or fluoroquinolone, combined with azithromycin or a fluoroquinolone for atypical coverage 4.
Newer agents: Ceftolozane-tazobactam demonstrates 96.5% susceptibility against ICU Pseudomonas isolates and may achieve adequate coverage as monotherapy where other beta-lactams require combination therapy 5. However, this is not yet incorporated into standard guidelines.
Common Pitfalls to Avoid
- Don't routinely use combination therapy for all patients—research shows combination therapy is associated with higher mortality in low and medium-risk groups compared to monotherapy (adjusted OR 1.54) 6
- Don't use standard intermittent infusions when prolonged infusions are feasible—they frequently fail to achieve pharmacodynamic targets 2
- Don't continue dual therapy once septic shock resolves and sensitivities are known 1
- Don't forget MRSA coverage if patient received IV antibiotics in prior 90 days or is in a unit with >20% MRSA prevalence—add vancomycin 15mg/kg IV q8-12h (target trough 15-20 mg/mL) or linezolid 600mg IV q12h 1